Shanghai Fosun Pharmaceutical Stock Retained Earnings
| SFOSFDelisted Stock | USD 1.70 0.00 0.00% |
Shanghai Fosun Pharmaceutical fundamentals help investors to digest information that contributes to Shanghai Fosun's financial success or failures. It also enables traders to predict the movement of Shanghai Pink Sheet. The fundamental analysis module provides a way to measure Shanghai Fosun's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Fosun pink sheet.
Shanghai |
Shanghai Fosun Pharmaceutical Company Retained Earnings Analysis
Shanghai Fosun's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Shanghai Fosun Retained Earnings | 10.37 B |
Most of Shanghai Fosun's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Fosun Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
CompetitionBased on the latest financial disclosure, Shanghai Fosun Pharmaceutical has a Retained Earnings of 10.37 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The retained earnings for all United States stocks is 11.14% lower than that of the firm.
Shanghai Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Fosun's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Shanghai Fosun could also be used in its relative valuation, which is a method of valuing Shanghai Fosun by comparing valuation metrics of similar companies.Shanghai Fosun is currently under evaluation in retained earnings category among its peers.
Shanghai Fundamentals
| Return On Equity | 0.0756 | |||
| Return On Asset | 0.0204 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 15.52 B | |||
| Shares Outstanding | 551.94 M | |||
| Shares Owned By Insiders | 0.07 % | |||
| Shares Owned By Institutions | 35.60 % | |||
| Price To Earning | 13.80 X | |||
| Price To Book | 1.45 X | |||
| Price To Sales | 0.31 X | |||
| Revenue | 39.01 B | |||
| Gross Profit | 18.71 B | |||
| EBITDA | 8.71 B | |||
| Net Income | 4.74 B | |||
| Cash And Equivalents | 14.64 B | |||
| Cash Per Share | 5.49 X | |||
| Total Debt | 9.05 B | |||
| Debt To Equity | 0.64 % | |||
| Current Ratio | 1.00 X | |||
| Book Value Per Share | 16.30 X | |||
| Cash Flow From Operations | 3.95 B | |||
| Earnings Per Share | 0.21 X | |||
| Number Of Employees | 36.28 K | |||
| Beta | 0.76 | |||
| Market Capitalization | 12.25 B | |||
| Total Asset | 93.29 B | |||
| Retained Earnings | 10.37 B | |||
| Working Capital | (817 M) | |||
| Current Asset | 10.27 B | |||
| Current Liabilities | 11.09 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 93.29 B | |||
| Last Dividend Paid | 0.56 |
About Shanghai Fosun Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Fosun Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Fosun using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Fosun Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Shanghai Pink Sheet
If you are still planning to invest in Shanghai Fosun Pharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Shanghai Fosun's history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |